Sagard Healthcare Partners /
MacroGenics, Inc.
Sagard to purchase MacroGenics royalty rights tied to ZYNYZ
What happened
Sagard Healthcare Partners agreed to purchase MacroGenics, Inc.’s rights to royalties on future global net sales of ZYNYZ. MacroGenics received a $70.0 million cash payment.
Sagard’s royalty receipts are capped at $140.0 million, after which MacroGenics will resume collecting future royalties.
The source
Everything on this page comes from the source below.
Sagard to purchase MacroGenics royalty rights tied to ZYNYZ
This document is the source for the companies, stage, figure and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly